These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

975 related items for PubMed ID: 22285225

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Preclinical evaluation of combined TKI-258 and RAD001 in hepatocellular carcinoma.
    Chan SL, Wong CH, Lau CP, Zhou Q, Hui CW, Lui VW, Ma BB, Chan AT, Yeo W.
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1417-25. PubMed ID: 23546591
    [Abstract] [Full Text] [Related]

  • 3. The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment.
    Gedaly R, Angulo P, Chen C, Creasy KT, Spear BT, Hundley J, Daily MF, Shah M, Evers BM.
    Anticancer Res; 2012 Jul; 32(7):2531-6. PubMed ID: 22753710
    [Abstract] [Full Text] [Related]

  • 4. Rapamycin and CCI-779 inhibit the mammalian target of rapamycin signalling in hepatocellular carcinoma.
    Hui IC, Tung EK, Sze KM, Ching YP, Ng IO.
    Liver Int; 2010 Jan; 30(1):65-75. PubMed ID: 19845851
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. HS-116, a novel phosphatidylinositol 3-kinase inhibitor induces apoptosis and suppresses angiogenesis of hepatocellular carcinoma through inhibition of the PI3K/AKT/mTOR pathway.
    Jung KH, Choi MJ, Hong S, Lee H, Hong SW, Zheng HM, Lee HS, Hong S, Hong SS.
    Cancer Lett; 2012 Mar 28; 316(2):187-95. PubMed ID: 22182943
    [Abstract] [Full Text] [Related]

  • 7. Vertical blockade of the IGFR- PI3K/Akt/mTOR pathway for the treatment of hepatocellular carcinoma: the role of survivin.
    Ou DL, Lee BS, Lin LI, Liou JY, Liao SC, Hsu C, Cheng AL.
    Mol Cancer; 2014 Jan 03; 13():2. PubMed ID: 24387108
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Growth inhibition by NVP-BEZ235, a dual PI3K/mTOR inhibitor, in hepatocellular carcinoma cell lines.
    Masuda M, Shimomura M, Kobayashi K, Kojima S, Nakatsura T.
    Oncol Rep; 2011 Nov 03; 26(5):1273-9. PubMed ID: 21725613
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
    deGraffenried LA, Friedrichs WE, Russell DH, Donzis EJ, Middleton AK, Silva JM, Roth RA, Hidalgo M.
    Clin Cancer Res; 2004 Dec 01; 10(23):8059-67. PubMed ID: 15585641
    [Abstract] [Full Text] [Related]

  • 11. Combination of temsirolimus and adriamycin exhibits an enhanced antitumor effect in hepatocellular carcinoma.
    Kang HG, Wang BZ, Zhang J, Liu MR, Li YX.
    Clin Res Hepatol Gastroenterol; 2017 Mar 01; 41(2):197-203. PubMed ID: 27863926
    [Abstract] [Full Text] [Related]

  • 12. Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells.
    Grabinski N, Ewald F, Hofmann BT, Staufer K, Schumacher U, Nashan B, Jücker M.
    Mol Cancer; 2012 Nov 20; 11():85. PubMed ID: 23167739
    [Abstract] [Full Text] [Related]

  • 13. Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels.
    Mahalingam D, Medina EC, Esquivel JA, Espitia CM, Smith S, Oberheu K, Swords R, Kelly KR, Mita MM, Mita AC, Carew JS, Giles FJ, Nawrocki ST.
    Clin Cancer Res; 2010 Jan 01; 16(1):141-53. PubMed ID: 20028765
    [Abstract] [Full Text] [Related]

  • 14. Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3.
    Chen KF, Chen HL, Liu CY, Tai WT, Ichikawa K, Chen PJ, Cheng AL.
    Biochem Pharmacol; 2012 Mar 15; 83(6):769-77. PubMed ID: 22230479
    [Abstract] [Full Text] [Related]

  • 15. Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models.
    Gozgit JM, Squillace RM, Wongchenko MJ, Miller D, Wardwell S, Mohemmad Q, Narasimhan NI, Wang F, Clackson T, Rivera VM.
    Cancer Chemother Pharmacol; 2013 May 15; 71(5):1315-23. PubMed ID: 23468082
    [Abstract] [Full Text] [Related]

  • 16. Gastric cancer growth control by BEZ235 in vivo does not correlate with PI3K/mTOR target inhibition but with [18F]FLT uptake.
    Fuereder T, Wanek T, Pflegerl P, Jaeger-Lansky A, Hoeflmayer D, Strommer S, Kuntner C, Wrba F, Werzowa J, Hejna M, Müller M, Langer O, Wacheck V.
    Clin Cancer Res; 2011 Aug 15; 17(16):5322-32. PubMed ID: 21712451
    [Abstract] [Full Text] [Related]

  • 17. Arenobufagin, a natural bufadienolide from toad venom, induces apoptosis and autophagy in human hepatocellular carcinoma cells through inhibition of PI3K/Akt/mTOR pathway.
    Zhang DM, Liu JS, Deng LJ, Chen MF, Yiu A, Cao HH, Tian HY, Fung KP, Kurihara H, Pan JX, Ye WC.
    Carcinogenesis; 2013 Jun 15; 34(6):1331-42. PubMed ID: 23393227
    [Abstract] [Full Text] [Related]

  • 18. The effect of mTOR inhibition alone or combined with MEK inhibitors on brain metastasis: an in vivo analysis in triple-negative breast cancer models.
    Zhao H, Cui K, Nie F, Wang L, Brandl MB, Jin G, Li F, Mao Y, Xue Z, Rodriguez A, Chang J, Wong ST.
    Breast Cancer Res Treat; 2012 Jan 15; 131(2):425-36. PubMed ID: 21394501
    [Abstract] [Full Text] [Related]

  • 19. Novel phosphoinositide 3-kinase/mTOR dual inhibitor, NVP-BGT226, displays potent growth-inhibitory activity against human head and neck cancer cells in vitro and in vivo.
    Chang KY, Tsai SY, Wu CM, Yen CJ, Chuang BF, Chang JY.
    Clin Cancer Res; 2011 Nov 15; 17(22):7116-26. PubMed ID: 21976531
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of mTOR enhances chemosensitivity in hepatocellular carcinoma.
    Tam KH, Yang ZF, Lau CK, Lam CT, Pang RW, Poon RT.
    Cancer Lett; 2009 Jan 18; 273(2):201-9. PubMed ID: 18824293
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 49.